Visceral obesity is a better predictor than generalized obesity for basal insulin requirement at the initiation of insulin therapy in patients with type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 93, Issue 2, 2011, Pages 174-178

  Kim, Mee Kyoung ^a   Jang, Eun Hee ^a   Son, Jang Won ^a   Kwon, Hyuk Sang ^a   Baek, Ki Hyun ^a   Lee, Kwang Woo ^a   Song, Ki Ho ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Insulin requirement; Insulin resistance; Visceral obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; TRIACYLGLYCEROL;

ABDOMINAL SUBCUTANEOUS FAT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL INSULIN REQUIREMENT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIET THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN INFUSION; INSULIN TREATMENT; INTRAABDOMINAL FAT; KINESIOTHERAPY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREDICTIVE VALUE; TRIACYLGLYCEROL BLOOD LEVEL; VISCERAL OBESITY; WAIST CIRCUMFERENCE;

ADULT; AGED; ALANINE TRANSAMINASE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INTRA-ABDOMINAL FAT; MIDDLE AGED; OBESITY; OBESITY, ABDOMINAL; PREDICTIVE VALUE OF TESTS; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 80051569604     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.04.009     Document Type: Article

References (21)

1. Umpierrez G.E., Smiley D., Zisman A., Prieto L.M., Palacio A., Ceron M., et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007, 30:2181-2186.
2. Hawkins J.B., Morales C.M., Shipp J.C. Insulin requirements in 242 patients with type II diabetes mellitus. Endocr Pract 1995, 1:385-389.
3. Yki-Järvinen H., Ryysy L., Nikkilä K., Tulokas T., Vanamo R., Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999, 130:389-396.
4. Ryysy L., Häkkinen A.M., Goto T., Vehkavaara S., Westerbacka J., Halavaara J., et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000, 49:749-758.
5. Hayashi T., Boyko E.J., McNeely M.J., Leonetti D.L., Kahn S.E., Fujimoto W.Y. Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans. Diabetes 2008, 57:1269-1275.
6. Mao C.S., Riegelhuth M.E., Van Gundy D., Cortez C., Melendez S., Ipp E. An overnight insulin infusion algorithm provides morning normoglycemia and can be used to predict insulin requirements in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997, 82:2466-2470.
7. Furnary A.P., Braithwaite S.S. Effects of outcome on in-hospital transition from intravenous insulin infusion to subcutaneous therapy. Am J Cardiol 2006, 98:557-564.
8. Schmeltz L.R., DeSantis A.J., Schmidt K., O'Shea-Mahler E., Rhee C., Brandt S., et al. Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia. Endocr Pract 2006, 12:641-650.
9. van der Kooy K., Seidell J.C. Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord 1993, 17:187-196.
10. Ferrannini E., Natali A., Bell P., Cavallo-Perin P., Lalic N., Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 1997, 100:1166-1173.
11. Klöting N., Fasshauer M., Dietrich A., Kovacs P., Schön M.R., Kern M., et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 2010, 299:E506-E515.
12. Thamer C., Machann J., Staiger H., Müssig K., Schwenzer N., Ludescher B., et al. Interscapular fat is strongly associated with insulin resistance. J Clin Endocrinol Metab 2010, 95:4736-4742.
13. Pou K.M., Massaro J.M., Hoffmann U., Lieb K., Vasan R.S., O'Donnell C.J., et al. Patterns of abdominal fat distribution: the Framingham Heart Study. Diabetes Care 2009, 32:481-485.
14. Eguchi Y., Eguchi T., Mizuta T., Ide Y., Yasutake T., Iwakiri R., et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol 2006, 41:462-469.
15. Chitturi S., Abeygunasekera S., Farrell G.C., Holmes-Walker J., Hui J.M., Fung C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379.
16. Verrijken A., Francque S., Mertens I., Talloen M., Peiffer F., Van Gaal L. Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients. Int J Obes (Lond) 2010, 34:899-907.
17. Biesenbach G., Bodlaj G., Pieringer H., Raml A. Insulin requirement after one year of insulin therapy in type 2 diabetic patients dependent on fasting C-peptide. Neth J Med 2008, 66:259-260.
18. Henry R.R., Gumbiner B., Ditzler T., Wallace P., Lyon R., Glauber H.S. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 1993, 16:21-31.
19. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.
20. DeFronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214-E223.
21. Holt R.I.G., Cockram C.S., Flyvbjerg A., Goldstein B.J. Textbook of diabetes 2010, A John Wiley & Sons, Chichester.